Frederic L.W.V.J. Schaper, MD, PhD, director of Epilepsy Network Mapping at the Center for Brain Circuit Therapeutics at Brigham and Women’s Hospital and an instructor of neurology at Harvard Medical ...

Please provide your email address to receive an email when new articles are posted on . Among 2,214 persons with epilepsy, 7.5% had MDD, and 4% had generalized anxiety disorder. Those on valproic acid ...

U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated ...

MOUNTAIN VIEW, Calif., December 08, 2025--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the ...

Medically reviewed by Diana Apetauerova, MD Key Takeaways Epilepsy is often linked to genetic factors, brain injuries, ...

LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with ...

You can expect most epilepsy cases to improve with antiseizure drugs. Surgery is an option if medications do not work for your epilepsy. You may eat a ketogenic diet to help with treatment-resistant ...

TOKYO, May 13, 2024 - (JCN Newswire) - - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house discovered antiepileptic drug (AED) ...

NASHVILLE, Tennessee ―The retention rate for the antiseizure drug perampanel (Eisai Co, Ltd) is more than 70% for adult patients with epilepsy, new research shows. In early results from the PERPRISE ...

Epilepsy is a common neurological disorder that affects millions of people worldwide. Characterized primarily by seizures, epilepsy can present in a variety of ways depending on the individual and the ...